Mesoblast Ltd. | Mutual Funds
Mutual Funds that own Mesoblast Ltd.
M&G Investment Funds (3) OEIC - Recovery Fund
52,711,349
10.92%
0
1.72%
03/29/2018
American Funds New Economy Fund
28,891,583
5.99%
0
0.18%
06/30/2018
American Funds Small Cap World Fund
11,435,497
2.37%
0
0.04%
06/30/2018
6,093,000
1.26%
0
21.64%
07/26/2018
Vanguard Total International Stock Index Fund
5,697,282
1.18%
0
0%
07/31/2018
5,127,840
1.06%
2,293,371
0.76%
12/31/2017
M&G International Specialist Equity Fund
3,559,396
0.74%
0
0.96%
03/29/2018
M&G Investment Funds (1) OEIC - Asian Fund
3,426,003
0.71%
0
0.79%
03/29/2018
Manulife Global Fund - Asian Small Cap Equity Fund
2,993,187
0.62%
761,419
1.22%
12/31/2017
Vanguard Australian Shares Index Fund
2,826,818
0.59%
16,730
0.04%
07/31/2018
| Address |
55 Collins Street
Melbourne Victoria (VIC) 3000
Australia
|
|
Employees
|
- |
| Website |
http://www.mesoblast.com |
| Updated |
07/08/2019 |
| Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia. |
